Keath, SJ, Kane, JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry
Thomas, P. The stable patient with schizophrenia–from antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol
2007; 17 (suppl 2): s115–22.
Weiden, P, Aquila, R, Standard, J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry
1996; 57 (suppl 11): s53–60.
Fenton, WS, Blyer, C, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull
1997; 23: 637–51.
Ucok, A, Polat, A, Cakir, S, Genc, A. One year outcome in first episode schizophrenia; predictors of relapse. Eur Arch Psychiatry Clin Neurosci
2006; 256: 37–43.
Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr Serv
2004; 55: 886–91.
Hawton, K, Sutton, L, Haw, C, Sinclair, J, Deeks, JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry
2005; 187: 9–20.
Zygmunt, A, Olfson, M, Boyer, CA, Mechanic, D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry
2002; 159: 1653–64.
Lincoln, TM, Wilhelm, K, Nestoriuc, Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res
2007; 96: 2232–45.
Lecompte, D, Pelc, I. A cognitive-behavioral program to improve compliance with medication in patients with schizophrenia. Int J Ment Health
Kemp, R, Kirov, G, Everitt, B, Hayward, P, David, A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry
Maneesakorn, S, Robson, D, Gournay, K, Gray, R. An RCT of adherenve therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs
2007; 16: 1302–12.
Gray, R, Wykes, T, Edmonds, M, Leese, M, Gournay, K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia. Cluster randomised controlled trial. Br J Psychiatry
2004; 185: 157–62.
O'Donnel, C, Donohoe, G, Sharkey, L, Owens, N, Migone, M, Harries, R, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ
2003; 327: 834–6.
Byerly, MJ, Fisher, R, Carmody, T, Rush, AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry
2005; 66: 997–1001.
Gray, R, Leese, M, Bindman, J, Becker, T, Burti, L, David, A, et al. Adherence therapy for people with schizophrenia. European multicenter randomised controlled trial. Br J Psychiatry
2006; 189: 508–14.
Staring, ABP, Mulder, CL, Van der Gaag, M, Selten, JP, Loonen, AJM, Hengeveld, MW. Understanding and improving treatment adherence in patients with psychotic disorders; a review and a proposed intervention. Curr Psychiatry Rev
2006; 2: 487–94.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
Tait, L, Birchwood, M, Trower, P. A new scale (SES) to measure engagement with community mental health services. J Ment Health
2002; 11: 191–8.
World Health Organization. Composite International Diagnostic Interview (version 2.1 Auto). WHO, 1997.
Kikkert, MJ, Dekker, JJM, Koeter, MWJ, Schene, AH. The Inventory of Medication Intake (IMI): validation of an instrument for assessing adherence to antipsychotic medication. In Medication Adherence in Patients with Schizophrenia (ed Kikkert, MJ): 113–32. Dissertation at the University of Amsterdam, 2010.
Wing, JK, Beevor, AS, Curtis, RH, Park, SB, Hadden, S, Burns, A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry
1998; 172: 11–8.
Kikkert, MJ, Barbui, C, Koeter, MWJ, David, AS, Leese, M, Tansella, M, et al. Assessment of medication adherence in patients with schizophrenia. The achilles heel of adherence research. J Nerv Men Dis
2008; 196: 274–81.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Staring, ABP, Mulder, CL, Duivenvoorden, HJ, De Haan, L, Van der Gaag, M. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between entipsychotic medication compliance and quality of life. Schizophr Res
2009; 113: 27–33.
Prieto, L, Sacristán, JA, Hormaechea, JA, Casado, A, Badía, X, Gómez, JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin
2003; 20: 827–35.
Lamers, LM, Stalmeier, PFM, McDonnell, J, Krabbe, PFM, Van Busschbach, JJ. Measuring the quality of life in cost-utility analyses: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd
2005; 149: 1574–8.
Birchwood, M, Smith, J, Drury, V, Healy, J, Macmillan, F, Slade, M. A self-report insight scale for psychosis: reliability, validity, and sensitivity to change. Acta Psychiatr Scand
1994; 89: 62–7.
Drayton, M, Birchwood, M, Trower, P. Early attachment experience and recovery from psychosis. Br J Psychol
1998; 37: 269–84.
Link, B, Struening, EL, Neese-Todd, S, Asmussen, S, Phelan, JC. On describing and seeking to change the experience of stigma. Psychiatr Rehabil Skills
2002; 6: 201–31.
Horvath, AO, Greenberg, LS. Development and validation of the working alliance inventory. J Consult Psychol
1989; 36: 223–33.
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Lawrence Erlbaum Associates, 1988.
O'Donoghue, B, Lyne, J, Hill, M, Larkin, C, Feeney, L, O'Callaghan, E. Involuntary admission from the patient's perspective. Soc Psychiatry Psychiatr Epidemiol
2010; 45: 631–8.
Valenstein, M, Kavanagh, J, Lee, T, Reilly, P, Dalack, GW, Grabowski, J, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull
Hewitt, J, Coffey, M. Therapeutic working relationship with people with schizophrenia: literature review. J Adv Nurs
2005; 52: 561–70.
Staring, ABP, Van der Gaag, M, Van den Berge, M, Duivenvoorden, HJ, Mulder, CL. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res
2009; 115: 363–9.
Rathod, S, Kingdon, D, Smith, P, Turkington, D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics – data on a previously published randomised controlled trial. Schizophr Res
2005; 74: 211–9.
Claassen, D, Fakhoury, WK, Ford, R, Priebe, S. Money for medication: financial incentives to improve medication adherence in assertive outreach. Psychiatr Bull
2007; 31: 4–7.
Patel, MX, David, AS. Medication adherence: predictive factors and enhancement strategies. Psychiatry
2007; 6: 357–61.